Italia markets closed

OPKO Health, Inc. (0KCS.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,2096+0,1400 (+13,09%)
Alla chiusura: 07:13PM GMT

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305 575 4100
https://www.opko.com

Settore/i
Settore
Impiegati a tempo pieno3.930

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Phillip Frost Ph.D.Chairman & CEO1,45MN/D1936
Dr. Jane H. Hsiao M.B.A., Ph.D.Vice Chairman & Chief Technical Officer1,36MN/D1947
Dr. Elias Adam Zerhouni M.D.President & Vice Chairman1,36MN/D1951
Mr. Adam E. LogalSenior VP, CFO, Chief Accounting Officer & Treasurer1,09MN/D1978
Mr. Steven D. Rubin Esq., J.D.Executive VP of Administration & Director1,22MN/D1960
Dr. Akhtar Ashfaq FACP, FASN, M.D.Senior Vice President of Clinical Research & Development and Medical Affairs - Opko RenalN/DN/DN/D
Dr. Gary J. Nabel M.D., Ph.D.Chief Innovation Officer & DirectorN/DN/D1955
Dr. Charles W. BishopChief Executive Officer of OPKO RenalN/DN/D1952
Dr. Antonio F. CruzPresident of Transition TherapeuticsN/DN/D1953
Mr. Hans BernerPresident of OPKO Health IberoamericaN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Governance aziendale

L'ISS Governance QualityScore di OPKO Health, Inc. al 1 marzo 2024 è 8. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 10; diritti degli azionisti: 3; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.